Pfizer beat fourth-quarter estimates as Covid sales fell, pointing to obesity trial progress and cost cuts in its post-Covid ...

To help answer common vaccine questions, we consulted Dr. Stanley Perlman, a professor at the University of Iowa’s Carver ...

Pfizer Balances COVID Drag With Pipeline Momentum in Latest Earnings Call The overall tone of Pfizer Inc.’s latest earnings call was cautiously optimistic, with management emphasizing underlying ...

A third dose of the Pfizer/BioNTech COVID-19 vaccine can "strongly" boost protection against the delta variant -- beyond the protection afforded by the standard two doses, suggests new data released ...

The 2025-26 Pfizer COVID-19 vaccine is about 57% effective against emergency department/urgent care (ED/UC) visits and 54% ...

Pfizer (NYSE:PFE) reported positive Phase 2b VESPER-3 data for its monthly injectable GLP-1 obesity therapy acquired from ...

Feb 3(Reuters) - Pfizer on Tuesday reported fourth-quarter earnings above Wall Street estimates, as sustained demand for ...

Pfizer PFE reported fourth-quarter 2025 adjusted earnings per share of 66 cents, which comprehensively beat the Zacks Consensus Estimate of 57 cents per share. Earnings rose 5% year over year.

NEW YORK -- A course of pills developed by Pfizer can slash the risk of being hospitalized or dying from COVID-19 by 89% if taken within three days of developing symptoms, according to results ...

(Reuters) - A U.S. Centers for Disease Control and Prevention (CDC) advisory panel will meet on Friday to review data on the COVID-19 vaccine developed by Pfizer Inc and BioNTech SE, with a vote ...